RECURRENCES OF RETINAL DETACHMENT AFTER RETINECTOMY: Causes and Outcomes.

PURPOSE: To evaluate the different mechanisms of retinal detachment recurrence after retinectomy for rhegmatogenous retinal detachment (RD) complicated by proliferative vitreoretinopathy (PVR) and to study its outcome and prognosis. METHODS: Retrospective, multicenter study conducted between January 2009 and November 2016. Retrospective review of 56 patients with recurrent RD (RRD) after a first relaxing retinectomy. RESULTS: The secondary retinal attachment rate was 58.9% (33/56 cases). The various mechanisms of RRD were mainly related to PVR (52/56 cases: 93%). This PVR was anterior in 10 cases (21%), posterior in 31 cases (60%), and combined anterior and posterior in 11 cases (21%). The RRD mechanism was not PVR in 4 of the 56 cases. Some of the RRD mechanisms were specific to retinectomy: fibrosis of the edge of the retinectomy (26 cases: 46.4%), beyond-the-edge proliferation (8 cases: 14.3%), and severe inferior retinal folding (2 cases: 3.6%). In the 2 cases of severe inferior retinal folding, the retina could not be reattached. The anatomical outcome and the mechanism of RRD (anterior PVR, posterior PVR, or combined anterior and posterior PVR) were not correlated (P = 0.12). Visual acuity was significantly better only in patients with complete secondary success, that is, having an attached retina after silicone oil removal: mean preoperative visual acuity was 2.01 logarithm of the minimum angle of resolution versus 1.01 logarithm of the minimum angle of resolution postoperatively (P = 0.019). CONCLUSION: Proliferative vitreoretinopathy caused most of the recurrences, and the anatomical outcome did not depend on the type of PVR involved. Only complete secondary success (attached retina after silicone oil removal) was accompanied by visual acuity improvement.

Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema.

PURPOSE: To evaluate the long-term efficacy and safety of the dexamethasone intravitreal implant Ozurdex® in the treatment of diabetic macular edema (DME). METHODS: This was a retrospective noncomparative study. A total of 23 patients with DME followed for at least 12 months were included. All patients were treated with at least 2 Ozurdex® injections for the treatment of DME. Best-corrected visual acuity, central retinal thickness, intraocular pressure (IOP), and cataract progression were recorded over 12 months. RESULTS: From baseline, the mean decrease in central retinal thickness was 315.9 µm at the 12th month and the mean best-corrected visual acuity improvement from baseline was 8.7 letters. Ozurdex® is administered via the extended release system Novadur®. Its efficacy extends beyond 4 months with a single injection and permits allows good stabilization until the 12th month, with 2.13 injections during this period. An increase in IOP was observed in 13.1% of patients and all were managed using topical IOP-lowering medications. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported. CONCLUSIONS: In real-life clinical practice, Ozurdex® has anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice.

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema.

PURPOSE: To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex®) in diabetic macular edema (DME). METHODS: This was a retrospective multicenter noncomparative study. Seventy-eight patients with DME followed for at least 6 months were included (P1.5 Network). Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP) and cataract progression were studied at baseline and then at 1, 2, 4 and 6 months. RESULTS: The mean CRT decrease from baseline was 145.2 µm at 6 months. The mean BCVA improvement from baseline was 6.7 at 6 months. An increase in IOP was observed for 11.7% of patients, and all patients were managed by topical treatment. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported. CONCLUSIONS: One injection of Ozurdex has an anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice. © 2015 S. Karger AG, Basel.

Electrophysiological retinal pigment epithelium changes observed with indocyanine green, trypan blue and triamcinolone.

BACKGROUND: Intravitreal application of indocyanine green (ICG), trypan blue (TB) or triamcinolone (TA) during vitreoretinal surgery has been associated with severe damage to the retinal pigment epithelium (RPE). However, the physiological background of these findings remains to be assessed. METHODS: In bovine RPE choroid preparations maintained in Ussing chambers, the effect of apical application of ICG, TA (filtered and not filtered) and TB at different concentrations was evaluated. The electrophysiological parameters (transepithelial potential, tissular resistance and short-circuit current) were continuously monitored. The experiments were conducted either in daylight or in dark-adapted conditions. RESULTS: After apical application of ICG and TA (purified and not purified), all bioelectrical parameters were affected in a dose-dependent manner. No significant changes were observed when the preparations were exposed to daylight. No changes were observed with TB. CONCLUSIONS: The electrophysiological results of apical application may explain the toxic effects observed after intraoperative use of ICG and TA. In this RPE study, TB appears to be the safest visualization aid for vitreoretinal surgery.

Quantification of metamorphopsia in patients with epiretinal membranes before and after surgery.

BACKGROUND: To evaluate quantification of metamorphopsia before and after the removal of unilateral epiretinal membrane (ERM). METHODS: One hundred and four consecutive patients with unilateral ERM scheduled for membrane peeling were prospectively enrolled. A complete ophthalmologic examination was performed. Metamorphopsia was evaluated, with standard Amsler grids and a laser grid generated with a scanning laser ophthalmoscope (SLO). The SLO procedure determined the area of distortion and was performed twice at a 30-minute interval to evaluate its reproducibility. The result was considered to be reliable when the area of distortion was identical in both SLO test sessions. One year after surgery, a complete ophthalmologic examination was performed. Metamorphopsia was again quantified with the SLO procedure. RESULTS: Before surgery, a reliable quantification of metamorphopsia (defined as area of distortion) could be performed in 98 patients (94%). Among these patients, 85 completed the follow-up of 12 months after surgery. Of these 85 patients, visual distortions had been detected preoperatively in 48 patients (56%). One year after surgery, visual distortions were detected in only 11 patients (13%). In 48 patients with preoperative distortions, the decrease of the area of distortion correlated with the change in visual acuity (r = -0.460, p = 0.011). CONCLUSIONS: SLO-based evaluation of metamorphopsia made it possible to provide a fast and reliable method for preoperative and post-operative quantification of visual distortion in patients undergoing ERM removal.